After five treatments, the tumor weight of V&siLTBR plus aPDL1‐treated mice was significantly lower than that of only V&siLTBR or aPDL1‐treated mice, suggesting that TAM‐targeted delivery of siLTBR could enhance the therapeutic effect of PDL1 antibody (Figure 6K,L). This evidence concerns the gene CD274 and neoplasm.